This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease

This study has been completed.
Information provided by (Responsible Party):
Johnson & Johnson K.K. Medical Company Identifier:
First received: August 1, 2010
Last updated: March 31, 2015
Last verified: March 2015
The main objective is to evaluate the safety and efficacy of SM-01 stenting (Cordis S.M.A.R.T.™ Nitinol Stent System) for the treatment of SFA lesions as compared to PTA (balloon angioplasty). If SM-01 is used in a PTA-bailout patient, the case will be assessed separately.

Condition Intervention Phase
Peripheral Vascular Diseases Device: SM-01 Device: PTA Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease

Further study details as provided by Johnson & Johnson K.K. Medical Company:

Primary Outcome Measures:
  • Non-TVF(Target-vessel failure) rate [ Time Frame: 12 Months ]
    The primary endpoint will be freedom from TVF defined as any events of clinical driven (confirmed by duplex ultrasound or angiography) TLR/TVR, procedure failure, amputation of the target lesion's leg, procedure or device related death, occlusion of target lesion, or > 70% restenosis of target lesion.

Secondary Outcome Measures:
  • Procedure Success rate [ Time Frame: 12 Months ]
  • Procedure Success rate for Bailout [ Time Frame: 12 Months ]
  • Difference between pre and post proceduer of ABI [ Time Frame: 12 Months ]
  • Difference between pre and post procedure of Rutherford Categories [ Time Frame: 12 Months ]
  • Non-TLR/TVR rate [ Time Frame: 12 Months ]
  • Primary Patency rate [ Time Frame: 12 Months ]
  • Stent Fracture rate [ Time Frame: 12 Months ]
  • Difference between pre and post procedure of QOL (SF-36) [ Time Frame: 12 Months ]
  • Major Clinical Event rate [ Time Frame: 12 Months ]

Enrollment: 105
Study Start Date: July 2010
Study Completion Date: August 2014
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SM-01 Device: SM-01
SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
Active Comparator: PTA Device: PTA
balloon angioplasty


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age >= 20 years.
  2. Symptomatic leg ischemia by Rutherford Classification (category1, 2, or 3).
  3. Lesion length >= 40 mm to <= 150 mm. (must be treatable with no more than two SM-01 stents. Overlap should be about 1cm if two stents are used)
  4. Reference vessel diameter (RVD) >= 4.0 mm and <= 7.0 mm.
  5. All lesions are to be located >= 3.0 cm proximal to the superior edge of the patella, and >= 1.0 cm distal to the SFA / PFA bifurcation.
  6. >= 50% stenosis or total occlusion.
  7. Patent infrapopliteal and popliteal arteries, i.e., single-vessel runoff or better with at least one of three vessels patent (< 50% stenosis) to the ankle or foot.
  8. Patient or legally authorized representative must provide written informed consent prior to initiation of study procedures.
  9. A patient with bilateral obstructive SFA disease is eligible for enrollment into the study. If a patient with bilateral disease is enrolled, the target limb will be the more severe limb. The more severe limb will be selected according to clinical symptomatology. If clinical symptomatology is similar, the more clinically severe lesion will be selected. The contralateral procedure should not be done until at least 30 days after the index procedure of the more severe limb was attempted.

Exclusion Criteria:

  1. Recent hemorrhagic disease within the past 3 months.
  2. Aneurysm in the SFA or popliteal artery.
  3. Acute limb occlusion.
  4. Procedures which are pre-determined to require stent-in-stent placement to obtain patency, such as severe calcification which is resistant to stenting, or for in-stent restenosis.
  5. Poor iliac or common femoral "inflow".(However, intervention to restore adequate blood flow prior to the treatment of the study lesion is allowed.)
  6. Known allergies to aspirin, heparin, or ticlopidine, or bleeding diathesis.
  7. Patients unable or unwilling to tolerate anticoagulant or antiplatelet therapy.
  8. Patients unable or unwilling to tolerate contrast agents used in intravascular procedures.
  9. Allergic to nitinol or tantalum.
  10. Women who are pregnant or lactating, or of child bearing potential, or with a desire to be a parent during the study period.
  11. Significant vessel tortuosity or other parameters prohibiting access to the lesion or which would prevent delivery of the stent device.
  12. Revascularization involving the same limb 30 days prior to the index procedure or a planned re-vascularization within 30 days after the index procedure.
  13. Previously implanted stent(s) at the same site in the artery to be treated.
  14. Requiring stent placement in the distal SFA or popliteal artery.
  15. Presence of a femoral artificial graft.
  16. History of participating in any other clinical study within 1 year.
  17. Life expectancy less than 3 years, or any other factors preventing clinical follow-up.
  18. Receiving dialysis or immunosuppressant therapy
  19. Serum creatinine level >= 2.0 mg/dL before procedure.
  20. A principal investigator or a co-principal investigator determines that patient is unsuitable for this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01183117

Toho University Ohashi Medical Center
Meguro-ku, Tokyo, Japan
Sponsors and Collaborators
Johnson & Johnson K.K. Medical Company
Principal Investigator: Hidehiko Hara, MD Toho University Ohashi Medical Center
  More Information

Responsible Party: Johnson & Johnson K.K. Medical Company Identifier: NCT01183117     History of Changes
Other Study ID Numbers: SM-01
Study First Received: August 1, 2010
Last Updated: March 31, 2015

Additional relevant MeSH terms:
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Cardiovascular Diseases
Arterial Occlusive Diseases processed this record on June 23, 2017